Cannabidiol Therapy for Angelman Syndrome With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no specific therapy for Angelman syndrome, and existing treatments for its symptoms such as seizures, learning disabilities, and motor dysfunction are inadequate, with CB1 agonists like THC having psychoactive side effects, and CB1 antagonists like rimonabant having serious side effects, leaving many patients with unmet needs.
Innovation Solution
The use of cannabidiol (CBD), either as a highly purified extract or synthetic compound, to treat Angelman syndrome, either alone or in combination with other medicaments, addressing symptoms such as movement disorders, anxiety, and cognitive dysfunction, with doses ranging from 0.1 to 100 mg/kg/day administered over an extended period.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat Angelman syndrome symptoms, then some symptom relief may be achieved, but significant side effects and limited efficacy occur
Solution Approach 1:
The patent changes the chemical parameter by using cannabidiol (CBD) instead of conventional medications. CBD interacts with the endocannabinoid system through CB1 and CB2 receptors, representing a different pharmacological mechanism that achieves symptom relief with reduced side effects compared to traditional treatments
2Ease of operation
If conventional treatments are administered, then some symptom management is achieved, but treatment complexity increases due to multiple medications needed
Solution Approach 1:
CBD serves multiple therapeutic functions simultaneously - it addresses seizures, movement disorders, anxiety, and cognitive dysfunction through a single agent. This multi-functionality simplifies the treatment regimen by replacing multiple specialized medications with one compound that acts on various symptom domains through its interaction with the endocannabinoid system
3Reliability
If no specific therapy is provided for Angelman syndrome, then current medications can be used, but they have inadequate efficacy for this specific condition
Solution Approach 1:
The patent introduces the endocannabinoid system as an intermediary mechanism for treating Angelman syndrome. CBD acts as a mediator that modulates neuronal excitability, synaptic transmission, and neuroinflammation through CB1 and CB2 receptors, providing a targeted therapeutic mechanism specifically suited for the pathophysiology of Angelman syndrome rather than generic symptom management
Data Source
AI summary
The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.